Airway diseases
Thematic poster
Chronic airway diseases and infections: management and prevalence
Methods :
Imaging, Respiratory intensive care, Epidemiology, Physiology, Pulmonary function testing, General respiratory patient care, Endoscopy and interventional pulmonology, Public health
“Smart” inhalers: is there a role in the management of severe asthma?
Y. See(Scarborough, United Kingdom)
COI
1
Utility of “smart” inhaler and suppression of fractional exhaled nitric oxide (FeNO): does it make a difference to patient outcomes?
E. Chow(Hull, United Kingdom)
COI
2
Dry powder inhaler (DPI) resistance: human behaviour and psychology of patient inspiratory effort
M. Stefanova Chakma(London, United Kingdom)
COI
3
Dry Powder Inhalers (DPIs) vs Metered Dose Inhaler (MDI) with valved spacer: Using Functional Respiratory Imaging (FRI) to assess modelled lung deposition in a COPD patient
J. Suggett(London (ON), Canada)
COI
4
Cardiovascular system side-effects of salbutamol: A systematic review and meta-analysis
X. Li(Shenzhen, China)
COI
5
Safety profile of triple ICS/LABA/LAMA FDC in the treatment of asthma: a meta-analysis
L. Calzetta(Roma (RM), Italy)
COI
6
Association of Short-Acting-β-2 Agonist (SABA) Overuse and Risk of COPD among Adult Asthma Patients
M. Asamoah-Boaheng(St John's, Canada)
COI
7
Improvement of asthma control after 3 months of treatment with extrafine single-inhaler triple therapy in asthmatics: a real-world view from Germany
T. Greulich(Marburg, Germany)
COI
8
Improvement of treatment adherence after 3 months of treatment with extrafine single-inhaler triple therapy in asthmatics: a real-world view from Germany
C. Gessner(Leipzig, Germany)
COI
9
Dose delivery characteristics and lung deposition of indacaterol/glycopyrronium/mometasone furoate (IND/GLY/MF) and IND/MF via Breezhaler device: An Alberta Idealised Throat (AIT) evaluation
X. Jaumont(La Madeleine, France)
COI
10
Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease and Risk of Acquiring Streptococcus Pneumoniae Infection. A Multiregional Epidemiological study
C. Heerfordt(Hellerup, Denmark)
COI
11
Disease burden and treatment patterns among patients with asthma on GINA 4/5 therapies in China
V. Benson(Uxbridge (Middlesex), United Kingdom)
COI
12
Disease burden and treatment patterns among patients with asthma in China
V. Benson(Uxbridge (Middlesex), United Kingdom)
COI
13
A randomised controlled trial of the effects of a total diet replacement programme in uncontrolled asthma associated with obesity
V. Sharma(Glasgow, United Kingdom)
COI
14
Two-month treatment with Zataria multiflora affected inflammatory cytokines, pulmonary function testes and respiratory symptoms in patients with chronic obstructive pulmonary disease (COPD)
M. Boskabady(Mashhad, Islamic Republic of Iran)
COI
15
The availability, cost and affordability of essential medicines for asthma and COPD in low- and middle-income countries: A systematic review
M. Stolbrink(Liverpool (Merseyside), United Kingdom)
COI
16
Characterization of a Colombian cohort of high-risk phenotypes of COPD according to GesEPOC 2021
C. Celis Preciado(Bogotá (Cundinamarca), Colombia)
COI
17
Physical activity, sedentary behaviour and sleep of Sri Lankan adults living with COPD: cross-sectional study
A. Jayamaha(Colombo, Sri Lanka)
COI
18
EDAC PREVALENCE AND ASSOCIATED FACTORS IN PATIENTS WITH SEVERE BRONCHIAL ASTHMA
I. Alfaya Fiaño(barcelona, Spain)
COI
19
Asthma patients discharged from the emergency department in Ireland: an unmet need?
R. Cusack(Waterford, Ireland)
COI
20
. . .
